Commentary
Video
Author(s):
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
FDA Grants Priority Review to Zongertinib for HER2-Mutant Advanced NSCLC
Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
FDA Grants Priority Review to Dordaviprone in Recurrent H3K27M+ Diffuse Glioma
Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
Five Under 5: Top Oncology Videos for the Week of 2/9
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management
TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma
Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC
Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber